Canetta R, Hilgard P, Florentine S, Bedogni P, Lenaz L
Cancer Chemother Pharmacol. 1982;7(2-3):93-8. doi: 10.1007/BF00254528.
The unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and Vepesid (VP16-213, etoposide), are stimulating the interest of both laboratory and clinical researchers. Investigations on new pharmaceutical formulations, pharmacokinetics and metabolism are providing more appropriate information in drug administration; experimental chemotherapy indicates that, among others, cytosine arabinoside and cisplatin are highly synergistic with podophyllotoxins; single agent and combination treatment clinical trials are defining the respective role of Vumon and Vepesid in cancer chemotherapy.
鬼臼毒素衍生物威猛（VM26，替尼泊苷）和威克（VP16 - 213，依托泊苷）独特的生物学特性及治疗效果激发了实验室研究人员和临床研究人员的兴趣。关于新药物制剂、药代动力学及代谢的研究为药物给药提供了更合适的信息；实验性化疗表明，除其他药物外，阿糖胞苷和顺铂与鬼臼毒素具有高度协同作用；单药及联合治疗的临床试验正在明确威猛和威克在癌症化疗中的各自作用。
